Navigation Links
Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
Date:2/25/2009

stockholder value. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks that the Company does not realize the cost savings or other benefits expected from the restructuring, risks associated with the Company's Wyeth collaboration, including Wyeth's control over development timelines, the risk that the estimated charges associated with the restructuring ultimately are larger than expected or that the estimated annual cost savings are lower than expected, and such other risks as are identified in the Company's quarterly report on Form 10-Q for the period ended Sept. 30, 2008, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the Company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Trubion Announces Presentations at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
3. Trubion Announces Presentations at Upcoming Investor Conferences
4. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
5. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
6. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
7. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
8. Trubion Announces Presentations at April/May Investor Conferences
9. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
10. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
11. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... January 13, 2014 Bob Hainsey, a ... than 20 years in the industry, has joined ... Hainsey will serve as the society’s Science and Technology ... join SPIE as our Technology Strategist, further strengthening the ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... BASINGSTOKE, England and PHILADELPHIA, Pennysylvania, March 3, Shire ... biopharmaceutical company, notes that Renovo Group plc, (LSE:,RNVO) ... latest Phase 2,studies of JUVISTA(R) (human recombinant TGFbeta3) ... (RN1001-319-1010)., Renovo’s press release can be found ...
... and MONTREAL, March 3 /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. ... company,focused on endocrine therapy and oncology, and Paladin ... company, announced today,that they have entered into a ... rights related to the manufacture, production, distribution,marketing, sale ...
... Feb. 29 Wyeth Pharmaceuticals,a division of Wyeth ... U.S. Food and,Drug Administration (FDA) has approved PRISTIQ(TM) ... treat adult patients with major depressive disorder (MDD). ... in the second,quarter of 2008., "We are ...
Cached Biology Technology:Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 2Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 3AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 2FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 4FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 5FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 6FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 7FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 8FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 9
(Date:4/20/2014)... gene expression analysis growing in importance for both ... Mellon University and the University of Maryland have ... up estimates of gene activity from RNA sequencing ... after the famously speedy fish, estimates of gene ... completed in a few minutes, with accuracy that ...
(Date:4/20/2014)... newborn baby a gift of germsgerms that help ... used to fend off infection, may paradoxically interrupt ... babies more susceptible to dangerous pathogens. , ... The Children,s Hospital of Philadelphia (CHOP) sheds light ... microbes play a crucial role in fostering the ...
(Date:4/20/2014)... crop residue to make ethanol and other biofuels reduces ... gasoline, according to a study published today in the ... by a University of Nebraska-Lincoln team of researchers cast ... meet federal mandates to ramp up ethanol production and ... stalks, leaves and cobs in cornfields after harvest -- ...
Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3
... called CD14 binds to substances liberated from the bacteria ... published in the Journal of Biological Chemistry, scientists in ... and showed how it is perfectly suited to bind ... the "Paper of the Week" in the March 25 ...
... number of genes we have in our genome—more than ... genetic truth has often been obscured. The expression of ... host of non-coding sequences, which bind transcription factors and ... coding sequences, whose signatures are easy to spot, the ...
... and MYC cooperate with each other to promote pediatric ... finding, from investigators at St. Jude Children's Research Hospital, ... Biology (MCB). , B-cell lymphoma is a cancer in ... crowd out other blood cells. The St. Jude researchers ...
Cached Biology News:Scientists solve structure of key protein in innate immune response 2Unexpressed But Indispensable -- The DNA Sequences That Control Development 2TEL2 gene cooperates with MYC gene to provoke B-cell lymphomas 2TEL2 gene cooperates with MYC gene to provoke B-cell lymphomas 3
...
Contains L-glutamine...
...
... ZMD.358. Immunogen: Synthetic peptide ... of human mouse and rat ... human and mouse LRP5 proteins. ... controls: mouse LRP5-pSEC-tag-transfected 293T cells ...
Biology Products: